Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3382 |
Name | liposarcoma |
Definition | A connective tissue cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3939 |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer liposarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 wild-type | MK-8242 | liposarcoma | predicted - sensitive | detail... |
TP53 wild-type | ALRN-6924 | liposarcoma | predicted - sensitive | detail... |
TP53 wild-type | KRT-232 | liposarcoma | predicted - sensitive | detail... |
TP53 wild-type | BI 907828 | liposarcoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00356031 | Phase II | Bevacizumab | Bevacizumab and Radiation Therapy for Sarcomas | Completed | USA | 0 |
NCT01506596 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | Completed | USA | 0 |
NCT02048371 | Phase II | Regorafenib | A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas | Completed | USA | 0 |
NCT02210104 | Phase I | Ipilimumab Cyclophosphamide | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | Withdrawn | 0 | |
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
NCT02301039 | Phase II | Pembrolizumab | A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | Completed | USA | 0 |
NCT02343172 | Phase Ib/II | Ribociclib + Siremadlin | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | Completed | FRA | ESP | DEU | CAN | 2 |
NCT02357810 | Phase II | Pazopanib + Topotecan | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Completed | USA | 0 |
NCT02606461 | Phase II | Selinexor | KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL) | Completed | USA | SWE | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT02846987 | Phase II | Abemaciclib | Study of Abemaciclib in Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
NCT02923778 | Phase II | Talimogene laherparepvec | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | Active, not recruiting | USA | CAN | 0 |
NCT02978859 | Phase II | Sitravatinib | MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas | Completed | USA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03074318 | Phase Ib/II | Avelumab + Trabectedin | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT03114527 | Phase II | Everolimus + Ribociclib | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | Active, not recruiting | USA | 0 |
NCT03190174 | Phase Ib/II | Nab-rapamycin + Nivolumab | Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma | Completed | USA | 0 |
NCT03307616 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03474094 | Phase II | Atezolizumab | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) | Recruiting | GBR | FRA | 0 |
NCT03548428 | Phase II | Atezolizumab | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) | Recruiting | FRA | 0 |
NCT03719430 | Phase II | Doxorubicin + Olaratumab + Sotigalimab | APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
NCT03880123 | Phase I | Ixazomib + Selinexor | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Withdrawn | USA | 0 |
NCT03899805 | Phase II | Eribulin + Pembrolizumab | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Active, not recruiting | USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT04076579 | Phase II | Olaparib + Trabectedin | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma | Active, not recruiting | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04216953 | Phase Ib/II | Atezolizumab + Cobimetinib | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) | Active, not recruiting | FRA | 0 |
NCT04242238 | Phase I | Avelumab + Vimseltinib | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | Active, not recruiting | USA | 0 |
NCT04420975 | Phase I | BO-112 + Nivolumab | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Recruiting | USA | SVK | GBR | CZE | ARG | 3 |
NCT04906876 | Phase II | Docetaxel + Elraglusib + Gemcitabine | 9-ING-41Combined With Chemotherapy in Adolescents and Adults | Withdrawn | USA | 0 |
NCT05116800 | Phase II | Docetaxel + Elraglusib + Gemcitabine | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Withdrawn | USA | 0 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT05836571 | Phase II | Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | Recruiting | USA | CAN | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT06025747 | Phase I | Abemaciclib | Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma | Recruiting | USA | 0 |
NCT06263231 | Phase III | Eribulin Trabectedin Pazopanib INT230-6 | A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (INVINCIBLE-3) | Recruiting | USA | 0 |
NCT06474676 | Phase I | AttIL12 T-cells Cyclophosphamide | T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. | Not yet recruiting | USA | 0 |
NCT06541262 | Phase Ib/II | Irinotecan + Silmitasertib + Temozolomide + Vincristine Sulfate Irinotecan + Silmitasertib + Temozolomide | Silmitasertib (CX-4945) in Combination with Chemotherapy for Relapsed Refractory Solid Tumors | Recruiting | USA | 0 |